Relay Therapeutics, Inc.
RLAY
$19.86
-$0.07-0.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 350.00K | 3.00M | 7.00M | -- | 677.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 350.00K | 3.00M | 7.00M | -- | 677.00K |
| Cost of Revenue | 76.48M | 70.56M | 56.34M | 67.89M | 63.90M |
| Gross Profit | -76.13M | -67.56M | -49.34M | -67.89M | -63.22M |
| SG&A Expenses | 14.69M | 11.03M | 13.59M | 12.50M | 13.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.17M | 81.59M | 69.93M | 80.39M | 77.52M |
| Operating Income | -90.82M | -78.59M | -62.93M | -80.39M | -76.85M |
| Income Before Tax | -83.71M | -73.29M | -54.89M | -74.15M | -70.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.71M | -73.29M | -54.89M | -74.15M | -70.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.71M | -73.29M | -54.89M | -74.15M | -70.38M |
| EBIT | -90.82M | -78.59M | -62.93M | -80.39M | -76.85M |
| EBITDA | -90.46M | -78.09M | -62.33M | -79.64M | -75.85M |
| EPS Basic | -0.41 | -0.41 | -0.32 | -0.43 | -0.41 |
| Normalized Basic EPS | -0.26 | -0.25 | -0.21 | -0.27 | -0.26 |
| EPS Diluted | -0.41 | -0.41 | -0.32 | -0.43 | -0.41 |
| Normalized Diluted EPS | -0.26 | -0.25 | -0.21 | -0.27 | -0.26 |
| Average Basic Shares Outstanding | 202.85M | 179.85M | 173.40M | 172.39M | 171.26M |
| Average Diluted Shares Outstanding | 202.85M | 179.85M | 173.40M | 172.39M | 171.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |